BioClinica (BIOC) Announces Clinical Trial Efficiency Improvements with Johnson and Johnson Vision Care
Tweet
Share
E-mailGet Alerts BIOC Hot Sheet
Join SI Premium – FREE
BioClinica Inc., (NASDAQ: BIOC) announced that Johnson and Johnson Vision Care (JJVC) (NYSE: JNJ), is ahead of its schedule to achieve efficiencies from its three-year electronic data capture (EDC) and data management agreement with BioClinica signed in October 2010, having reached its target in less than one year.
Johnson and Johnson Vision Care (JJVC) achieved its goal of running paperless clinic studies by using Express EDC for direct data entry while streamlining the study build process. BioClinica data management services are utilized to assure that all data is cleaned and processed in a timely manner. The reduction in the overall study development time to produce study results allows the business to react faster to make important and informed decisions. Studies are built and deployed faster, and study data are available for analysis soon after the last patient last visit (LPLV).
Johnson and Johnson Vision Care (JJVC) achieved its goal of running paperless clinic studies by using Express EDC for direct data entry while streamlining the study build process. BioClinica data management services are utilized to assure that all data is cleaned and processed in a timely manner. The reduction in the overall study development time to produce study results allows the business to react faster to make important and informed decisions. Studies are built and deployed faster, and study data are available for analysis soon after the last patient last visit (LPLV).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Solana Company announces votes on first Solana governance proposals
- UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
